Literature DB >> 11299769

Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells.

X Wang1, J R Masters, Y C Wong, A K Lo, S W Tsao.   

Abstract

Cisplatin is used in the treatment of many tumours, including nasopharyngeal carcinoma (NPC). In this study, we studied two nasopharyngeal cancer cell lines with a four-fold difference in sensitivity to cisplatin. Following exposure to cisplatin, the sensitive SUNE1 cell line underwent apoptosis while the relatively resistant CNE1 line died through mitotic cell death. No differences were seen in telomere length or in the cell cycle distribution after cisplatin treatment. However, there was an increase in Bax levels in the sensitive cell line SUNE1, while in the resistant line CNE1 that did not undergo apoptosis, Bax levels fell. Our results suggest that upregulation of Bax is associated with the sensitivity of these NPC cells to cisplatin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11299769

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Amplification of chromosome 8q21-qter associated with the acquired paclitaxel resistance of nasopharyngeal carcinoma cells.

Authors:  Wei Li; Yating You; Xiaowei Zhang; Yexun Song; Hong Xiang; Xiaowei Peng; Jiangbo Qin; Guolin Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma.

Authors:  Yanjie You; Wenjun Yang; Xin Qin; Fei Wang; Haijun Li; Canfeng Lin; Wenmei Li; Cunguo Gu; Yinpo Zhang; Yonggang Ran
Journal:  Cell Oncol (Dordr)       Date:  2015-02-24       Impact factor: 6.730

3.  Hippo pathway contributes to cisplatin resistant-induced EMT in nasopharyngeal carcinoma cells.

Authors:  Shuo Li; Xiaomeng Zhang; Rongkai Zhang; Zibin Liang; Wei Liao; Zhengde Du; Chunsheng Gao; Fei Liu; Yunping Fan; Haiyu Hong
Journal:  Cell Cycle       Date:  2017-07-27       Impact factor: 4.534

4.  Zoledronic acid reverses cisplatin resistance in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathway.

Authors:  Yanjie You; Haijun Li; Jiongyu Chen; Xin Qin; Yonggang Ran
Journal:  Oncol Lett       Date:  2017-01-18       Impact factor: 2.967

5.  The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells.

Authors:  Youxiang Hou; Qianling Zhu; Zheng Li; Yongbo Peng; Xiaohui Yu; Bowen Yuan; Yijun Liu; Youhong Liu; Linglong Yin; Yuchong Peng; Zhenghua Jiang; Jinping Li; Bowen Xie; Yumei Duan; Guolin Tan; Kurban Gulina; Zhicheng Gong; Lunquan Sun; Xuegong Fan; Xiong Li
Journal:  Cell Death Dis       Date:  2017-03-09       Impact factor: 8.469

6.  Implication of hsa_circ_0028007 in reinforcing migration, invasion, and chemo-tolerance of nasopharyngeal carcinoma cells.

Authors:  Dong Qiongna; Zhang Jiafeng; Hao Yalin; He Ping; Zhou Chuan; Jin Xiaojie; Zhao Miaomiao; Shao Yiting; Zhao Hui
Journal:  J Clin Lab Anal       Date:  2020-06-11       Impact factor: 2.352

7.  Long non-coding RNA LINC00346 contributes to cisplatin resistance in nasopharyngeal carcinoma by repressing miR-342-5p.

Authors:  Zheqing Cui; Tian Pu; Yujie Zhang; Jia Wang; Yulin Zhao
Journal:  Open Biol       Date:  2020-05-13       Impact factor: 6.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.